This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic

Hypereosinophilic Syndrome Clinical Trial

Official title:
104317: An Open-Label Compassionate Use Access and Long-Term Access Study of Anti IL-5 (Mepolizumab) Treatment in Subjects With Hypereosinophilic Syndrome. 201956: A Long-term Access Programme for Subjects With Severe Asthma Who Participated in a GSK-sponsored Mepolizumab Clinical Study. 112562: Expanded Access to Mepolizumab for Patients With Hypereosinophilic Syndrome

Status No longer available

Clinical Trial Summary

104317: The market authorisation application for mepolizumab for the indication of hypereosinophilic syndrome (HES) was filed in 2008, but later the file was withdrawn due to outstanding questions from regulator's raised from the application. On the basis of sponsor's evaluation, participants with life-threatening HES who have documented failure (lack of efficacy or a contra-indication) to at least 3 standard HES therapies (compassionate use) and participants who have participated in a previous GSK sponsored study in HES (long-term access) can be consider for mepolizumab treatment where the country regulation permits. In this study, participants will receive mepolizumab in an open-labelled manner, and limited data will be collected to evaluate the long-term safety and efficacy of mepolizumab. 201956: This is a Long-term Access Programme (LAP) which aims to support provision of mepolizumab, until it is commercially available, to eligible subjects with severe asthma who participated in a GSK-sponsored mepolizumab clinical study in severe asthma. Eligible subjects will initiate mepolizumab within a 6-month period following the individual subject's last scheduled visit in their preceding clinical study. For each subject benefit versus risk will be assessed throughout the study to support continued treatment with mepolizumab. 112562: To provide a mechanism for expanded access to mepolizumab therapy for eligible patients with HES. Whenever possible, use of an investigational medicinal product by a patient as part of a clinical trial is preferable. However, when patient enrollment in a clinical trial is not possible (such as when the patient is not eligible for ongoing clinical trials or the patient is not able to attend investigational sites), appropriate patients may receive mepolizumab through expanded access. This expanded access protocol was designed to allow access to mepolizumab for HES patients with seriously debilitating or life-threatening disease that are not able to enroll in clinical trials, including those patients that have already participated in a mepolizumab clinical trial.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00244686
Study type	Expanded Access
Source	GlaxoSmithKline
Contact
Status	No longer available
Phase

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05334368` - Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial	Phase 3
Recruiting	`NCT00044304` - Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome	Phase 2
Completed	`NCT00171912` - Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes	Phase 2
Completed	`NCT00097370` - Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome	Phase 3
Terminated	`NCT00171860` - A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome	Phase 2
Recruiting	`NCT02581514` - Eosinophilia Diagnosis	N/A
Completed	`NCT00787384` - Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes	Phase 2
Recruiting	`NCT03801434` - Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders	Phase 2
Completed	`NCT00255346` - Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)	Phase 2
Completed	`NCT03306043` - A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622	Phase 3
Recruiting	`NCT04018118` - Natural History of Hypereosinophilia and Hypereosinophilic Syndromes
Completed	`NCT02836496` - Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)	Phase 3
Completed	`NCT00086658` - Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)	Phase 3
Recruiting	`NCT00276926` - Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias	Phase 2
Active, not recruiting	`NCT02101138` - Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome	Phase 2
Recruiting	`NCT00091871` - A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
Completed	`NCT01713504` - Identification of New Markers in the Hypereosinophilic Syndrome	N/A
Completed	`NCT00038675` - Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate	N/A
Completed	`NCT00017862` - Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome	Phase 2
Terminated	`NCT00230334` - Phase II Gleevec Idiopathic Hypereosinophilic Syndrome	Phase 2